Supplementary Figures 1 - 7 from Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma
Anjali Mishra,Krista La Perle,Sonya Kwiatkowski,Larry E.Sullivan,Gregory H. Sams,Jessica Johns,Douglas P. Curphey,Jinyu Wen,Kathleen McConnell,Jun Qi,Henry Ν. C. Wong,Giandomenico Russo,Jianying Zhang,Guido Marcucci,James E. Bradner,Pierluigi Porcu,Michael A. Caligiuri
DOI: https://doi.org/10.1158/2159-8290.22531310
2023-01-01
Abstract:Supplementary Figures 1 - 7. Supplementary Figure 1. Immunoblot analysis of IL-15 in normal donor CD4+ T-cells, SS patient CD4+ T-cells and patient derived cell lines. Supplementary Figure 2. Representative flow cytometric histogram is shown for CD3 expression in mononuclear cells from skin of WT and IL-15 tg mice. Supplementary Figure 3. Immunoblot analysis of HDAC1 in normal donor CD4+ T-cells, SS patient CD4+ T-cells and patient derived cell line, Hut78. Protein lysates were probed for expression of HDAC1; β-Actin was used as housekeeping control. Supplementary Figure 4. Immunoblot analysis for expression of p21 protein in normal donor CD4+ cells following ten days of incubation in IL-15 compared to unstimulated normal donor CD4+ T-cells. Supplementary Figure 5. Pie chart showing the distribution of HDAC1 occupancy in normal donor CD4+ T-cells (upper left) compared to patient CD4+ T-cells (upper right) and normal donor CD4+ T-cells stimulated with 100ng/ml IL-15 for 24 hours (lower left). Supplementary Figure 6. High magnification and (B) low magnification histological analysis of IL-15 Tg skin. Supplementary Figure 7. The CTCL mouse disease severity scoring system is on a 0 to 100 scale, with 100 being the highest (most severe) score.